AlgoTherapeutix

What AlgoTherapeutix does

AlgoTherapeutix SAS (AlgoTx) is a clinical-stage French biotechnology company founded in April 2018 and headquartered in Suresnes, France. It develops ATX01, a proprietary high-concentration topical amitriptyline hydrogel formulated to deliver a tricyclic antidepressant locally to damaged sensory nerve fibers in the skin of the hands and feet, selectively inhibiting nociceptive voltage-gated sodium channels Nav1.7, Nav1.8, and Nav1.9. The product targets two peripheral neuropathic pain indications with no FDA-approved therapies: chemotherapy-induced peripheral neuropathy (CIPN), where 68% of chemotherapy patients are affected (~2M+ patients annually in the US and Europe), and erythromelalgia, a rare neurovascular pain condition. ATX01 has received FDA Fast Track Designation in CIPN and Orphan Drug Designation in both the US and EU for erythromelalgia, and is protected by a global patent portfolio.

The company completed a 276-patient international Phase 2 ACT trial in CIPN across 40+ sites in the US and Europe, with results reported in February 2025 showing statistically significant superiority versus placebo at the 15% concentration in a post-hoc analysis of low-placebo sites, while the overall intent-to-treat analysis was confounded by a high placebo effect in some sites. A parallel Phase 2 EASE study for erythromelalgia was conducted at Mayo Clinic and Erlangen University Hospital. AlgoTx is led by an experienced pharma team (CEO Stéphane Thiroloix, ex-Ipsen/Smith&Nephew; CMO Gabriel Fox, ex-Roche; CSO Philippe Picaut, ex-Ipsen) and a board that includes representatives from Bpifrance, Omnes, Turenne, and UI Investissement alongside independent directors with Pfizer and Cadence Pharmaceuticals backgrounds.

AlgoTx is pre-revenue, with cumulative funding of approximately €35M raised across a €2.6M seed (January 2019), a €0.5M Bpifrance grant (November 2019), a €12M Series A (November 2020), and a €20M Series B (March 2023). Its intended business model is to commercialize ATX01 post-approval through a partnership with a large pharmaceutical company, generating revenue from product sales and/or licensing for the US and European markets, while additional indications (painful diabetic neuropathy, phantom limb pain) are planned as pipeline extensions.

Name

AlgoTherapeutix

Legal name

AlgoTherapeutix SAS

Website

https://algotx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

AlgoTherapeutix is a French clinical-stage biotech developing ATX01, a proprietary topical amitriptyline hydrogel targeting peripheral sodium channels (Nav1.7/1.8/1.9) to treat chemotherapy-induced peripheral neuropathy and erythromelalgia, with plans to commercialize via a large-pharma partner post-approval.

Ownership category

akta.pro rank

Product category

Neuropathic Pain Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)

akta.pro secondary industry

Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)

Keywords

• Topical pain therapeutics
• Neuropathic pain treatment
• Chemotherapy-induced neuropathy
• Biopharmaceutical drug development
• Topical amitriptyline formulation

Headquarters

HQ city

Suresnes

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotech. Once ATX01 receives regulatory approval, the company intends to commercialize it through a pharma partnership for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) and potentially other peripheral neuropathic pain indications. Revenue will be generated from product sales, initially focused on the US and European markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

AlgoTherapeutix is developing ATX01, a proprietary topical hydrogel formulation of high-concentration amitriptyline designed to treat chemotherapy-induced peripheral neuropathy (CIPN) and erythromelalgia. The drug is applied to the skin of hands and feet to selectively inhibit nociceptive sodium channels (Nav1.7, Nav1.8, Nav1.9) in peripheral sensory nerve fibers, blocking pain signaling while minimizing systemic exposure and associated side-effects.

Product overview

AlgoTherapeutix is a clinical-stage biotechnology company developing a single core product, ATX01, a proprietary topical formulation of amitriptyline for the treatment of peripheral neuropathic pain conditions. The company's primary focus is on ATX01 in chemotherapy-induced peripheral neuropathy (CIPN), where it has completed Phase 2 clinical development. ATX01 is applied topically as a hydrogel to target pain-signaling nerve fibers in the skin, selectively inhibiting nociceptive sodium channels (Nav1.7, Nav1.8, Nav1.9) while minimizing systemic exposure. The product was also previously developed for erythromelalgia under Orphan Drug Designation from FDA and EMA, but development was discontinued after Phase 2 did not show superiority over placebo. The company also plans to explore ATX01 in additional indications such as Painful Diabetic Peripheral Neuropathy and Phantom Limb Pain following the CIPN program.

Differentiator

Problem solved

Functional benefit

Products and services

• ATX01

Quantifiable outcome

• Phase 2 ACT trial: ATX01 15% showed statistically significant superiority to placebo on most primary and secondary endpoints in post-hoc analysis at low-placebo sites, with 1.6-point reduction on NPRS pain scale.
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Worldwide Clinical TrialscoreImplementation/ SI/ Consulting PartnerWorldwide Clinical Trials is AlgoTx's CRO (Contract Research Organization) partner supporting the conduct of Phase 2 clinical trials (ACT and EASE studies) in CIPN and erythromelalgia across multiple international sites.
• Mayo Clinic (USA)coreStrategic or Co-development PartnerMayo Clinic in Rochester, US, is a key clinical trial site for the Phase 2 EASE study in erythromelalgia, led by Dr. Julio Sartori Valinotti. Mayo Clinic is one of the leading medical institutions globally, providing clinical trial infrastructure and patient access.
• Erlangen University Hospital (Germany)coreStrategic or Co-development PartnerUniversitaetsklinikum Erlangen Hautklinik in Germany is the European clinical trial site for the Phase 2 EASE study in erythromelalgia, led by Dr. Juergen Bauerschmitz. The study was also approved by the German regulatory agency BfArM.
• Professor Guido Cavaletti (University of Milano-Bicocca)supportingStrategic or Co-development PartnerProfessor Guido Cavaletti serves as the scientific lead and principal investigator for the Phase 2 ACT study in CIPN. He is Professor of Neurology at University of Milano-Bicocca, BoD of the Peripheral Nerve Society, and Chair of the Toxic Neuropathy Consortium.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Vertex Pharmaceuticals: Vertex's VX-548 (suzetrigine) is an FDA-approved non-opioid pain therapeutic (NaV1.8 inhibitor) for acute pain, making it the closest mechanistic and clinical parallel to AlgoTx's Nav1.7/1.8/1.9 topical approach for neuropathic pain.
• Collegium Pharmaceutical: Specialty pain pharmaceutical company with approved products (Xtampza, Belbuca) in chronic pain; broader incumbent providing market context for pain commercialization dynamics.
• Pfizer: Major pharma with established pain franchise (Lyrica, Neurontin) and historical leadership in neuropathic pain — relevant as a potential commercial partner for AlgoTx's ATX01.
• Lilly (Eli Lilly): Large pharma with significant neuropathic pain and neurology pipeline activity, including Nav1.8 inhibitor programs — a relevant comparator and potential commercial partner.

Direct peers

• Aptinyx: Clinical-stage biotech developing NMDA-receptor modulators for neuropathic pain (e.g., NYX-2925), directly comparable in stage, indication focus (neuropathic pain), and small-cap clinical profile.
• Lexicon Pharmaceuticals: Developed LX9211 (AAK1 inhibitor) for diabetic peripheral neuropathic pain, a comparable clinical-stage neuropathic pain program with similar trial and indication dynamics.
• Cara Therapeutics: Developed Korsuva (difelikefalin) for chronic pruritus and has pursued neuropathic pain indications; comparable as a small-cap clinical-stage pain-focused biotech.

Emerging players

• Tonix Pharmaceuticals: Clinical-stage company with pain and CNS pipeline programs, comparable in stage and therapeutic area focus (central and peripheral pain modulation).
• Acadia Pharmaceuticals: Neurology-focused pharma with pain and CNS assets; an AlgoTx board member (Edmund Harrigan) serves on Acadia's board, indicating shared networks and a comparable specialty-pharma profile.
• BioXcel Therapeutics: Clinical-stage biotech with neuroscience and pain-adjacent pipeline programs (e.g., BXCL501), comparable as a small-cap neurology/pain biotech pursuing FDA approval pathways.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/algotherapeutix

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles25 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AlgoTherapeutix